http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이민수,김용구,김영훈,연병길,오병훈,윤도준,윤진상,이철,정희연,강병조,김광수,김동언,김명정,김상훈,김희철,나철,노승호,민경준,박기창,박두병,백기청,백인호,손봉기,손진욱,양병환,양창국,우행원,이정호,이종범,이홍식,임기영,전태연,정영조,정영철,정인과,정인원,지익성,채정호,한상익,한선호,한진희,서광윤 大韓神經精神醫學會 1998 신경정신의학 Vol.37 No.1
연구목적 : 본 시험의 목적은 임상시험 시작전에 연구자들을 대상으로 PANSS Workshop을 통하여 PANSS, ESRS에 대한 국내에서의 표준화 작업을 구축하고 새로운 정신병 치료제인 리스페리돈의 효과와 안정성을 재확인하여 리스페리돈 사용에 대한 적정화를 이루는데 있다. 연구방법 : 1996년 4월부터 1996년 9월까지 국내 39개 대학병원 정신과에 입원중인 혹은 증상이 악화되어 입원하는 정신분열병 환자 377명을 대상으로 다시설 개방 연구를 시행하였다. 1주일간의 약물 배설기간을 가진후, 리스페리돈을 8주간 투여하였고, 기준점, 1주, 2주, 4주, 그리고 8주후에 평가되었다. 용량은 제1일에는 리스페리돈 1mg씩 1일 2회, 제2일에는 2mg씩 1일 2회, 제3∼7일에는 3mg씩 1일 2회 투여하였다. 이후 환자의 임상상태에 따라 임의로 증량할 수 있으며, 최대 일일 16mg을 초과하지 않도록 하였다. 추체외로 증상을 조절하기 위한 투약을 허용하였다. 임상증상 및 부작용의 평가는 PANSS(Positive and Negative Syndrome Scale), CGI(Clinical Global Impression) 그리고 ESRS(Extrapyramidal Symptom Rating Scale)을 사용하였다. 연구결과 : 377명중 343명(91%)이 8주간의 연구를 완결하였다. 치료 종결시점인 8주후 PANSS 총점수가 20% 이상 호전된 경우를 약물 반응군으로 정의할때, 약물반응군은 81.3%였다. 리스페리돈에 반응하는 예측인자로는 발병연령, 이전의 입원 횟수, 유병기간이 관련 있었다. 리스페리돈은 1주후부터 PANSS양성, 음성, 및 일반정신병리 점수상에 유의한 호전을 보여 효과가 빨랐다. CGI의 경우도 기준점에 비해 1주후부터 유의한 감소를 나타내었다. ESRS의 경우, 파킨슨 평가점수는 기준점과 비교해 투여 1주, 2주, 4주후 유의하게 증가되었다가 8주후 기준점과 차이가 없었다. Dystonia 평가점수는 1주후만 유의한 증가를 보였으며, dyskinesia 평가점수는 유의한 차이가 없었다. 혈압, 맥박수의 생명징후 및 일반 혈액학 검사, 생화학적 검사, 심전도 검사에서 유의한 변화는 없었다. 결 론 : 이상의 다시설 개방 임상 연구를 통해 리스페리돈은 정신분열병 환자에서 양성증상뿐만 아니라 음성증상 및 전반적인 증상에도 효과적인 것으로 사료된다. 보다 명확한 평가를 위해서는 다른 항정신병약물과의 이중맹검 연구가 필요할 것으로 생각되며, 또한 장기적 치료에 대한 평가도 함께 이루어져야 하겠다. Objective : The purpose of this study was to investigate the efficacy and safety of risperidone in the treatment of Korean schizophrenic patients. Method : This multicenter open study included 377 schizophrenic patients drawn from 39 university hospitals. After a wash-out period of 1 week, the schizophrenic patients were treated with risperidone for 8 weeks and evaluated at 5 points ; at baseline, and 1, 2, 4 and 8 weeks of treatment. The dose was increased from 2mg/day(1mg twice daily) to 6mg/day(3mg twice daily) during the first week and adjusted to a maximum of 16mg/day over the next 7 weeks according to the patient's clinical response. Medication to control extrapyramidal symptoms was permitted. The psychiatric and neurological status of the patients was assessed by PANSS, CGI, and ESRS scales. Results : 343(91%) of 377 patients completed the 8-week trial period. Clinical improvement, as defined by a 20% or more reduction in total PANSS score at end point, was shown by 81.3% of patients. The predictors of response to risperidone were associated older age, shorter duration of illness, fewer previous hospitalization. Risperidone had rapid onset of action ; a significant decrease of the total PANSS and three PANSS factor(positive, negative, general), and CGI was already noticed at the end of first week. For the ESRS, parkinsonism rating scores were significantly increased until week 4 comparing with baseline. Dystonia rating scores were significantly increased until week 1, and dyskinesia rating scores were not significantly changed during the study. Laboratory parameters including vital sign, EKG, hematological, and biochemical values showed no significant changes during the trial. Conclusions : This study suggests that risperidone is generally safe and effective against both the positive and negative symptoms in our group of patients.
( Min Ha Kook ),( Myong Joo Hong ),( Wan Hee Yoo ) 대한내과학회 2011 대한내과학회 추계학술발표논문집 Vol.2011 No.1
A 21-year-old woman was presented with low back pain, both knees and right ankle pain that had lasted for several months. Physical examination showed butterfly rash over the cheeks, and tenderness on both hip and knee joints and right Achilles tendon. Labortory examination showed leukocyte count 3,260/μL, ESR 97 mm/hr, CRP 63.19 mg/L, positive antinuclear antibody, Anti-dsDNA antibody, 40.9 IU/ml, C3 83.4 mg/dL, and C4 18.2 mg/dL. Rheumatoid factor and HLA B27 were negative. X-ray revealed bilateral sacroiliitis. Ankylosing spondylitis (AS) was diagnosed based on low back pain and bilateral sacroilliitis. Also she fullfilled five ACR criteria for systemic lupus erythematosus (SLE); malar rash, arthralgia, leukopenia, positive for ANA, and positive for anti-dsDNA antibody. The patient treated with 5 mg of prednisolone, hydroxychloroquine 200 mg/day, sulfasalazine 1,000 mg/day and NSAIDs. Overlapping of diverse clinical features is one of the main characteristic of rheumatic disease. Over 90 percent of patients with SLE suffer joint symptoms such as arthritis or arthralgia during their illness and AS is the chief spondyloarthritis that involves axial joints. Although there is still a debate on the relationship between AS and SLE, the coexistence of SLE and AS is a very rare rheumatic disease entity. Here, we report a new case of coexistence of AS and SLE in a female patient.
국민하 ( Min Ha Kook ),김인재 ( In Jae Kim ),백초옥 ( Cho Ok Baek ),이창훈 ( Chang Hun Lee ),장지원 ( Ji Won Jang ),오호준 ( Ho Jun Oh ),최경화 ( Kyoung Hwa Choi ),정치량 ( Chi Ryang Chung ),박승용 ( Seung Yong Park ),박성주 ( Seo 전북대학교 의과학연구소 2011 全北醫大論文集 Vol.35 No.2
Tracheobronchopathia osteochondroplastica (TO) is a rare, benign condition and is characterized by the presence of bony and cartilaginous nodules in the tracheal and bronchial submucosa. Bronchoscopy remains the gold standard for the diagnosis of TO and characteristically reveals multiple, submucosal nodules measuring 1 to 10 mm in diameter. The lesions are found most frequently in the distal two thirds of the trachea and the involvement of the lobar and more peripheral bronchial tree is very rare. Here, we report a patient with right middle lobe syndrome caused by tracheopathia osteochondroplastica.
손민정 ( Min Jeong Son ),이하정 ( Ha Jeong Lee ),오국환 ( Kook Hwan Oh ),주권욱 ( Kwon Wook Joo ),김성권 ( Sunhn Gwon Kim ) 대한신장학회 2009 Kidney Research and Clinical Practice Vol.28 No.5
Renal vein thrombosis (RVT) is mostly related with other causes. The underlying conditions of RVT were nephrotic syndrome, trauma, cancer, anatomical anomalies, and other hypercoagulable status. Especially hypercoagulable status was rarely caused by obesity. We diagnosed renal vein thrombosis from an obese patient with hypertriglyceridemia. A male patient visited the Seoul National University Hospital for evaluating the reason of his flank pain. The pain started from two weeks ago, He had regarded flank pain as his obesity status (his weight was 84 kg and Body mass index was 29.41 kg/m2). So he had lost his weight by over-sweating one day before. At initial examination, his blood pressure was 128/75 mmHg, pulse rate was 72/min, respiration rate was 20/min and body temperature was 36.2℃. Blood chemistries revealed total cholesterol 218 mg/dL, Blood urea nitrogen/creatinine 12/1.3 mg/dL Urinalysis showed specific gravity 1.015, pH 5.5, protein 2+, blood 2+, RBC/WBC 1-4/<1 HPF on microscopic examination. Twenty-four hour collection of the urine showed protein 329 mg/day, creatinine clearance 90 mL/min. Renal vein thrombosis was visualized on the renal computed tomography and pulmonary embolism on the lung scan. Then, anticoagulant therapy was started after coagulation related tests. However, no abnormality of coagulation tests was detected. The evidence of malignancy was not detected either. After anticoagulation therapy, the pain was subsided. The only underlying cause for his hypercoagulability was considered obese status. Unfortunately we had not checked the triglyceride, initially. So we could not prioritize the reason of renal vein thrombosis into hypertriyglyceridemia. We considered that his obese status and subsequent hypertriyglyceridemia might be one of the causes of renal vein thrombosis.
An Efficient Parallel Algorithm for the Single Function Coarsest Partition Problem on the EREW PRAM
Ha, Kyeoung-Ju,Ku, Kyo-Min,Park, Hae-Kyeong,Kim, Young-Kook,Ryu, Kwan-Woo Electronics and Telecommunications Research Instit 1999 ETRI Journal Vol.21 No.2
In this paper, we derive an efficient parallel algorithm to solve the single function coarsest partition problem. This algorithm runs in O(\log2n) time using O(nlogn) operations on the EREW PRAM with O(n) memory cells used. Compared with the previous PRAM algorithms that consume O(n1+${\varepsilon}$) memory cells for some positive constant ${\varepsilon}\>0$, our algorithm consumes less memory cells without increasing the total number of operations.